From €3131EUR$3,600USD￡2,786GBP
From €3131EUR$3,600USD￡2,786GBP
- Report
- June 2020
- 216 Pages
From €2700EUR$3,104USD￡2,402GBP
€3000EUR$3,449USD￡2,669GBP
- Report
- June 2020
- 114 Pages
From €3697EUR$4,250USD￡3,289GBP
- Drug Pipelines
- May 2020
- 3473 Pages
From €2174EUR$2,500USD￡1,935GBP
From €3131EUR$3,600USD￡2,786GBP
- Report
- May 2020
- 116 Pages
From €3697EUR$4,250USD￡3,289GBP
- Report
- May 2020
- 112 Pages
From €3697EUR$4,250USD￡3,289GBP
From €861EUR$990USD￡766GBP
From €1035EUR$1,190USD￡921GBP
From €3470EUR$3,990USD￡3,087GBP
From €3470EUR$3,990USD￡3,087GBP
- Report
- March 2020
- 104 Pages
From €3914EUR$4,500USD￡3,482GBP
- Drug Pipelines
- February 2020
- 880 Pages
From €1740EUR$2,000USD￡1,548GBP
- Drug Pipelines
- February 2020
- 106 Pages
From €1740EUR$2,000USD￡1,548GBP
- Drug Pipelines
- February 2020
- 106 Pages
From €1740EUR$2,000USD￡1,548GBP
- Drug Pipelines
- February 2020
- 106 Pages
From €1740EUR$2,000USD￡1,548GBP
- Report
- February 2020
- 120 Pages
From €3697EUR$4,250USD￡3,289GBP
- Drug Pipelines
- February 2020
- 106 Pages
From €2174EUR$2,500USD￡1,935GBP
- Drug Pipelines
- February 2020
- 106 Pages
From €2174EUR$2,500USD￡1,935GBP
Lymphoma encompasses a variety of blood cancers of the lymphatic system. Non-Hodgkin’s Lymphoma (NHL) for example, is diagnosed in over 100,000 every year in the US and EU combined. An array of expert reports in our Lymphoma Section enable you to investigate drug development strategies and market trends for NHL, Hodgkin’s Lymphoma, Skin Lymphoma, T-Cell Lymphoma, Indolent Lymphoma and other variants. Investigate key issues such as licensing, R&D, industry alliances, generic drugs (rituximab, bortezomib, doxorubicin, bleomycin, vinblastine, etc.) and the activities of major pharmaceutical players such as Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Show Less Read more
